[HTML][HTML] Etanercept as monotherapy in patients with psoriasis
…, BS Goffe, R Zitnik, A Wang, AB Gottlieb - … England Journal of …, 2003 - Mass Medical Soc
Background Inflammatory cytokines such as tumor necrosis factor (TNF) have been implicated
in the pathogenesis of psoriasis. We evaluated the safety and efficacy of etanercept, a …
in the pathogenesis of psoriasis. We evaluated the safety and efficacy of etanercept, a …
Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional …
…, JM Gelfand, KB Gordon, AB Gottlieb… - Journal of the American …, 2009 - Elsevier
Psoriasis is a common, chronic, inflammatory, multisystem disease with predominantly skin
and joint manifestations affecting approximately 2% of the population. In this fourth of 6 …
and joint manifestations affecting approximately 2% of the population. In this fourth of 6 …
Interleukin 6 is expressed in high levels in psoriatic skin and stimulates proliferation of cultured human keratinocytes.
…, TS Kupper, PB Sehgal, AB Gottlieb - Proceedings of the …, 1989 - National Acad Sciences
Psoriasis is a common papulosquamous skin disease. The histopathology is characterized
by epidermal hyperplasia and inflammation. Recent studies suggest that keratinocyte …
by epidermal hyperplasia and inflammation. Recent studies suggest that keratinocyte …
Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled …
…, R Landewé, PG Conaghan, AB Gottlieb… - The Lancet, 2015 - thelancet.com
Background Interleukin 17A is a proinflammatory cytokine that is implicated in the pathogenesis
of psoriatic arthritis. We assessed the efficacy and safety of subcutaneous secukinumab, …
of psoriatic arthritis. We assessed the efficacy and safety of subcutaneous secukinumab, …
Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial
IB McInnes, A Kavanaugh, AB Gottlieb, L Puig… - The Lancet, 2013 - thelancet.com
Background Many patients with psoriasis develop psoriatic arthritis, a chronic inflammatory
disease that afflicts peripheral synovial, axial, and entheseal structures. The fully human …
disease that afflicts peripheral synovial, axial, and entheseal structures. The fully human …
Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis
SL Gottlieb, P Gilleaudeau, R Johnson, L Estes… - Nature medicine, 1995 - nature.com
Psoriasis is a hyperproliferative and inflammatory skin disorder of unknown aetiology. A fusion
protein composed of human interleukin-2 and fragments of diphtheria toxin (DAB 389 IL-2)…
protein composed of human interleukin-2 and fragments of diphtheria toxin (DAB 389 IL-2)…
Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics
…, JM Gelfand, KB Gordon, AB Gottlieb… - Journal of the American …, 2019 - Elsevier
Psoriasis is a chronic, inflammatory multisystem disease that affects up to 3.2% of the US
population. This guideline addresses important clinical questions that arise in psoriasis …
population. This guideline addresses important clinical questions that arise in psoriasis …
Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and …
…, MK Doyle, AM Mendelsohn, AB Gottlieb… - Annals of the …, 2014 - ard.bmj.com
… Alice B Gottlieb8, … Proton Rahman Lluis Puig Alice B Gottlieb Shu Li Yuhua Wang Lenore
Noonan Carrie Brodmerkel Michael Song Alan M Mendelsohn Iain B McInnes on behalf of the …
Noonan Carrie Brodmerkel Michael Song Alan M Mendelsohn Iain B McInnes on behalf of the …
Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial
AB Gottlieb, R Evans, S Li, LT Dooley, CA Guzzo… - Journal of the American …, 2004 - Elsevier
… Alice B. Gottlieb MD, PhD a , Robert Evans PharmD b , Shu Li MS b , Lisa T. Dooley DrPH
… Disclosure: Drs Gottlieb and Menter have received research support from and served as …
… Disclosure: Drs Gottlieb and Menter have received research support from and served as …
Treatment recommendations for psoriatic arthritis
…, D Fiorentino, O FitzGerald, AB Gottlieb… - Annals of the …, 2009 - ard.bmj.com
Objective: To develop comprehensive recommendations for the treatment of the various
clinical manifestations of psoriatic arthritis (PsA) based on evidence obtained from a systematic …
clinical manifestations of psoriatic arthritis (PsA) based on evidence obtained from a systematic …